Exploring the causal relationship between antihypertensive drugs and glioblastoma by combining drug target Mendelian

Songyun Zhao1,2, Yi Xie3, Xu Ding2

  • 1Department of Neurosurgery, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China.

PubMed

Insights

Beta-blockers (BBs) targeting the β1-adrenergic receptor (ADRB1) may reduce glioblastoma multiforme (GBM) risk by lowering blood pressure. Lower ADRB1 gene expression in malignant gliomas correlates with poor prognosis, suggesting a link between BBs and GBM development.

Area of Science:

  • Genetics and Genomics
  • Oncology
  • Pharmacology

Background:

  • Emerging evidence suggests antihypertensive drugs may play a role in cancer development.
  • The specific impact of these drugs on glioblastoma multiforme (GBM) risk remains unclear.
  • Understanding the relationship between blood pressure, antihypertensive medications, and GBM is crucial for patient outcomes.

Purpose of the Study:

  • To investigate the potential causal relationship between blood pressure (BP) and GBM risk.
  • To assess the influence of specific antihypertensive drug classes on GBM development.
  • To explore the role of the β1-adrenergic receptor (ADRB1) in GBM pathogenesis.

Main Methods:

  • Utilized genome-wide association study (GWAS) summary statistics for systolic BP (SBP), diastolic BP (DBP), and GBM in European populations.
  • Employed Mendelian randomization analysis with single nucleotide polymorphisms (SNPs) as instrumental variables for five antihypertensive drug classes.
  • Performed sensitivity and colocalization analyses to confirm findings; analyzed ADRB1 gene expression in GBM using TCGA and single-cell RNA sequencing data.

Main Results:

  • β-receptor blockers (BBs) targeting ADRB1 significantly reduced GBM risk by mediating both DBP (OR=0.431) and SBP (OR=0.595).
  • Sensitivity and colocalization analyses supported the robustness of the observed causal effects.
  • Low ADRB1 gene expression was identified in malignant gliomas, correlating with poorer GBM patient prognosis.

Conclusions:

  • This study provides preliminary evidence suggesting a causal link between ADRB1-targeted BBs and reduced GBM risk.
  • The findings highlight the potential role of ADRB1 in glioblastoma development and prognosis.
  • Further research is warranted to validate these results and elucidate the complex interplay between BP management and GBM.